Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.
2.

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.

Morrato EH, Druss B, Hartung DM, Valuck RJ, Allen R, Campagna E, Newcomer JW.

Arch Gen Psychiatry. 2010 Jan;67(1):17-24. doi: 10.1001/archgenpsychiatry.2009.179.

PMID:
20048219
3.

Assessment of monitoring for glucose and lipid dysregulation in adult Medi-Cal patients newly started on antipsychotics.

Barnett M, VonMuenster S, Wehring H, Popish S, McDonald K, Walker VM, Perry P.

Ann Clin Psychiatry. 2010 Feb;22(1):9-18.

PMID:
20196978
4.

Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients.

Morrato EH, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J.

J Clin Psychopharmacol. 2009 Feb;29(1):26-32. doi: 10.1097/JCP.0b013e31819294cb.

PMID:
19142103
5.

Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.

Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ.

Clin Ther. 2007 Jan;29(1):183-95.

PMID:
17379060
6.

Metabolic screening in children receiving antipsychotic drug treatment.

Morrato EH, Nicol GE, Maahs D, Druss BG, Hartung DM, Valuck RJ, Campagna E, Newcomer JW.

Arch Pediatr Adolesc Med. 2010 Apr;164(4):344-51. doi: 10.1001/archpediatrics.2010.48. Erratum in: Arch Pediatr Adolesc Med. 2010 Jun;164(6):584.

PMID:
20368487
7.

[Metabolic testing rates after initiation of antipsychotic treatment in persons initially treated by conventional mood-stabilizers].

Verdoux H, Gaudron Y, Auleley GR, Deligne J, Blum-Boisgard C, ThiƩbaut A, Tournier M.

Encephale. 2013 May;39 Suppl 1:S22-8. doi: 10.1016/j.encep.2012.10.009. Epub 2012 Dec 13. French.

PMID:
23246328
8.

Small area variation and geographic and patient-specific determinants of metabolic testing in antipsychotic users.

Morrato EH, Druss BG, Hartung DM, Valuck RJ, Thomas D, Allen R, Campagna E, Newcomer JW.

Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):66-75. doi: 10.1002/pds.2062. Epub 2010 Nov 15.

PMID:
21182154
9.

Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.

Moeller KE, Rigler SK, Mayorga A, Nazir N, Shireman TI.

Schizophr Res. 2011 Mar;126(1-3):117-23. doi: 10.1016/j.schres.2010.11.015. Epub 2010 Dec 18.

PMID:
21168994
10.

Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes.

Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B.

Diabetes Care. 2009 Jun;32(6):1037-42. doi: 10.2337/dc08-1720. Epub 2009 Feb 24.

11.

How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs.

Valuck RJ, Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R; Medicaid Pharmacotherapy Research Consortium..

Curr Med Res Opin. 2007 Oct;23(10):2567-76.

PMID:
17848204
12.

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.

Shi L, Ascher-Svanum H, Chiang YJ, Zhao Y, Fonseca V, Winstead D.

BMC Psychiatry. 2009 Dec 18;9:80. doi: 10.1186/1471-244X-9-80.

13.

Retrospective analysis of diabetes care in California Medicaid patients with mental illness.

Banta JE, Morrato EH, Lee SW, Haviland MG.

J Gen Intern Med. 2009 Jul;24(7):802-8. doi: 10.1007/s11606-009-0994-9. Epub 2009 May 5.

14.

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC.

J Clin Psychiatry. 2004 Oct;65(10):1377-88.

PMID:
15491242
15.

Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.

Weissman EM, Zhu CW, Schooler NR, Goetz RR, Essock SM.

J Clin Psychiatry. 2006 Sep;67(9):1323-6.

PMID:
17017817
16.

Population-based hepatitis C surveillance and treatment in a national managed care organization.

Shatin D, Schech SD, Patel K, McHutchison JG.

Am J Manag Care. 2004 Apr;10(4):250-6.

17.

Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.

Segal JB, Dy SM, Millman EA, Herbert R, Bass EB, Wu A.

Clin Ther. 2007 Aug;29(8):1784-94.

PMID:
17919559
18.

Measurement of Metabolic Monitoring in Youth and Adult Medicaid Recipients Prescribed Antipsychotics.

Edelsohn GA, Parthasarathy M, Terhorst L, Karpov IO, Schuster J.

J Manag Care Spec Pharm. 2015 Sep;21(9):769-77, 777a-777cc.

19.

Use patterns for antipsychotic medications in medicaid patients with schizophrenia.

McCombs JS, Nichol MB, Stimmel GL, Shi J, Smith RR.

J Clin Psychiatry. 1999;60 Suppl 19:5-11; discussion 12-3.

20.

Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia.

Lambert BL, Chang KY, Tafesse E, Carson W.

J Clin Psychopharmacol. 2005 Feb;25(1):12-8.

PMID:
15643095

Supplemental Content

Support Center